In this article, we will discuss Durvalumab (Biliary Tract Cancer-2). So, let’s get started.
Durvalumab was discontinued due to adverse reactions in 6% of the patients receiving Durvalumab plus chemotherapy. The most frequently reported events resulting in discontinuation were sepsis (3 patients) and ischemic stroke (2 patients). The remaining events were dispersed across system organ classes and reported in 1 patient each. Serious adverse reactions occurred in 47% of patients receiving Durvalumab plus chemotherapy. The most frequent serious adverse reactions reported in at least 2% of patients were cholangitis (7%), pyrexia (3.8%), anemia (3.6%), sepsis (3.3%) and acute kidney injury (2.4%).